Incannex Healthcare ($IXHL) Announces Positive Topline Results from Pharmacokinetics Study

Incannex develops combination medicines targeting chronic conditions like obstructive sleep apnea (OSA), rheumatoid arthritis, and generalized anxiety disorder. Its novel, evidence-based treatments address conditions with limited or no approved therapies.
Learn more here: incannex.com/
Follow me on Stocktwits: stocktwits.com...
Business Inquiries: [e-mail]
__________________________________________________________________________________
My UA-cam videos are for informational purposes only and not financial advice. I'm not a licensed financial professional, and nothing here is a recommendation to buy or sell any asset. Consult your financial advisor, and do your own research to take full responsibility for your decisions. I'm not liable for any losses.
This distribution was conducted on behalf of Incannex Healthcare Inc. (NASDAQ:IXHL) and was funded by Outside The Box Capital Inc. and/or affiliates after Undervalued Investor was engaged by Outside The Box Capital Inc. to advertise for Incannex Healthcare Inc. (NASDAQ:IXHL).
For our full disclaimer, please visit:bit.ly/414UK2T